Clinical trial
Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection and an Oral Solution of Betamethasone in Healthy Subjects
NCT05531890 is registered in ClinicalTrials.gov with Grace Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection and an Oral Solution of Betamethasone in Healthy Subjects
- Lead sponsor
- Grace Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 13, 2022
- Completion date
- May 3, 2023
- Enrollment
- 48 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.